CVM Orders Centaurus to Launch R$6 Billion OPA for Oncoclínicas

Reversing its technical staff, the CVM collegiate mandated the offer and set in motion a multi‑billion‑reais payout as arbitration and court challenges proceed.

Overview

The CVM collegiate voted unanimously to require Centaurus’s Josephina III fund to carry out a statutory public tender offer, a decision announced after the board met on Tuesday.
The mandated OPA is valued by market sources at more than R$6 billion and implies a per‑share price above R$16, a large premium to the current market quote near R$1.7.
The dispute stems from a November 2024 reorganization of Goldman Sachs’ stake that left a Centaurus vehicle above the 15% trigger in Oncoclínicas’ bylaws, activating the company’s poison‑pill clause.
Centaurus has already filed for arbitration at B3’s CAM to contest the commercial claim and plans to challenge the CVM outcome, while minority investors are organizing federal lawsuits to try to enforce the OPA independently.
The ruling lands as Oncoclínicas remains in extrajudicial recovery with about R$5.1 billion in liabilities, a mix that could reshape creditor recoveries, shareholder payouts and how regulators treat complex fund reorganizations.